SuperworthDanaher Corporation DHR
Medical - Diagnostics & Research, Healthcare
$218.49
+1.34%
- Market cap
- $153.6B
- PE
- 38.8×
- 10y median 36.4×
- Forward PE
- Price to sales
- 6.1×
- EV/EBIT
- 34.3×
- Revenue, 12 months
- $25.1B
- +5% on a year ago
- Net margin
- 15.9%
- Free cash flow yield
- 3.6%
Danaher trades at 38.8× trailing earnings, near its ten-year median. Revenue was $25.1B over the last twelve months, up 5% on a year earlier with a 16% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.4B | $5.8B | $5.7B | $5.8B | $6.5B+2% | $5.7B−1% | $5.9B+3% | $6.1B+4% | $6.8B+5% | $6B+4% | $6.3B+6% | |
| Cost of revenue | $2.6B | $2.3B | $2.3B | $2.4B | $2.6B+1% | $2.2B−3% | $2.4B+4% | $2.5B+6% | $2.9B+9% | $2.4B+6% | $2.7B+10% |
| Gross profit | $3.8B | $3.5B | $3.4B | $3.4B | $3.9B+3% | $3.5B+1% | $3.5B+3% | $3.5B+4% | $4B+2% | $3.6B+2% | $3.6B+3% |
| R&D | $407M | $368M | $391M | $383M | $442M+9% | $379M+3% | $403M+3% | $378M−1% | $438M−1% | $387M+2% | $412M+2% |
| SG&A | $2B | $1.8B | $1.9B | $2.1B | $2B−1% | $1.9B+3% | $2.4B+26% | $2B−3% | $2B+0% | $1.9B+0% | $2.1B−12% |
| $1.3B | $1.3B | $1.2B | $958M | $1.7B+31% | $1.3B−3% | $760M−35% | $1.2B+21% | $1.5B−14% | $1.3B+6% | $1.1B+48% | |
| Interest expense | $85M | $65M | $65M | $87M | $61M−28% | $72M+11% | $71M+9% | $67M−23% | $55M−10% | $63M−13% | −$107M |
| Pre-tax income | $1.2B | $1.3B | $1.1B | $977M | $1.3B+7% | $1.1B−11% | $655M−40% | $1.1B+10% | $1.4B+4% | $1.2B+9% | $1.1B+65% |
| $111M | $183M | $176M | $159M | $229M+106% | $175M−4% | $100M−43% | $168M+6% | $190M−17% | $206M+18% | $208M+108% | |
| Net income | $1.1B | $1.1B | $907M | $818M | $1.1B+1% | $954M−12% | $555M−39% | $908M+11% | $1.2B+10% | $1B+8% | $870M+57% |
| $1.45 | $1.45 | $1.22 | $1.12 | $1.49+3% | $1.32−9% | $0.77−37% | $1.27+13% | $1.68+13% | $1.45+10% | $1.23+60% | |
| 746.1M | 748.6M | 742.4M | 729.4M | 737.2M−1% | 720.8M−4% | 719.1M−3% | 713.7M−2% | 711M−4% | 711.2M−1% | 707.6M−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Danaher's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| Peer median | $40.4B | 34.5× | 32.8× | 6.5× | +8% | 15.0% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .